- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 09.12.25 | Avalere Health appoints Sarah Hall as President of US Marketing | ||
| 09.12.25 | Global regulatory standards | ||
| 08.12.25 | Pfizer's Hympavzi significantly reduces bleeds in haemophilia patients | ||
| 08.12.25 | Gilead's Yescarta shows benefits for patients with large B-cell lymphoma | ||
| 08.12.25 | Patient insight: human vs AIHCPS | ||
| 05.12.25 | Bridging the affordability gap | ||
| 05.12.25 | Vandria announces positive phase 1 data for Alzheimer's treatment | ||
| 05.12.25 | NRG Therapeutics appoints Paul Thompson as Chief Development Officer | ||
| 04.12.25 | Roche receives FDA clearance for whooping cough test | ||
| 04.12.25 | TRIMTECH Therapeutics appoints Alison Lawton as Chair of the Board | ||
| 04.12.25 | Why bad habits are sabotaging your strategic decisions | ||
| 03.12.25 | Richard Pazdur, FDA's drug evaluation chief, to leave FDA just weeks into new role | ||
| 03.12.25 | Circle Pharma appoints Anne Borgman as Chief Medical Officer | ||
| 02.12.25 | UK and US agree on landmark pharma pricing tariff deal | ||
| 02.12.25 | Danish diabetes-tech company Hedia appoints Rasmus Kofoed as CEO | ||
| 01.12.25 | Eisai submits new drug application for subcutaneous Leqembi in Japan | ||
| 01.12.25 | AstraZeneca's Imfinzi receives FDA approval for gastric and gastro-oesophageal cancers | ||
| 28.11.25 | Novartis' Itvisma gets FDA approval for spinal muscular atrophy treatment | ||
| 28.11.25 | Regeneron's Libtayo receives EC approval for skin cancer | ||
| 28.11.25 | ESMO 2025 - ensuring innovation isn't lost in translation | ||
| 27.11.25 | Sandoz launches first and only multiple sclerosis biosimilar in US | ||
| 27.11.25 | Tonix launches new oral fibromyalgia treatment | ||
| 27.11.25 | Agility in medical affairs: responding to rapid market and regulatory shifts | ||
| 27.11.25 | Optimised therapy to improve outcomes for heart attack and stroke patients | ||
| 27.11.25 | The new era of medical affairs: busting myths and supercharging strategic value |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.